Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing…
News
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence…
Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out…
Tilray Brands Announces Enhancements to Accretive Strategic Transaction with HEXO
Amended Terms Include Increased Discount on Purchase Price of HEXO Note and Reduced Tilray Conversion…
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA…
Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer
– Dr. Aspeslet joins the Company to support rencofilstat’s clinical program – EDISON, N.J., June…
Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage…
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries
BRIDGEWATER, N.J., June 14, 2022 (GLOBE NEWSWIRE) — Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing…
Day One Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq:…
Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022
Dr. Kellum Invited to Participate on Additional Featured Panels TORONTO, June 14, 2022 (GLOBE NEWSWIRE)…
The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities
The Biogen Foundation has granted $70 million to help underserved communities in advancing science education,…
Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
– Seasoned Life Science Executive Brings Expertise in Ophthalmic Clinical Development, Including Advancement of Multiple…
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at…
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) — Sio Gene Therapies Inc….
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company…
Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia
— Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SCB-219M in…